What happened to the Blackmores (ASX:BKL) share price last earnings season?

Here we peel back the onion on what happened when Blackmores last reported earnings.

| More on:
blackmores share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Blackmores Limited (ASX: BKL) share price has climbed just over 2% in the last month. In comparison, the S&P/ASX 200 index (ASX: XJO) is up 1.5% over the same period.

In early trading today, the Blackmores share price is up 0.56% at $78.97 apiece.

As the nutritional supplement company prepares to report its FY21 earnings on Thursday, let's take a look at what happened to the Blackmores share price last earnings season back in February.

What did Blackmores deliver in its half year results?

Blackmores detailed a pattern of growth in its FY21 half-year results in February, including:

  • Revenue of $302.6 million that grew 4% on a constant currency basis
  • International and China revenue growth of 13% and 25% respectively
  • 10% decline in ANZ revenue to $148 million
  • Net profit after tax (NPAT) of $19.4 million, an 8% increase from the year prior
  • Fully franked interim dividend of 29 cents per share.

While Blackmores did not shed any colour on guidance expectations, it did state that revenue in H2 would be "slightly lower" than H1.

Furthermore, it announced it would hand back $2.4 million of the $10.4 million in Jobkeeper assistance provided by the government for COVID-19 relief.

How did the Blackmores share price react?

The results were well received by the market, as investors drove the Blackmores share price north in the days following the announcement.

Blackmores shares climbed around 10% in the two days after the report, peaking at $81.41 before retracing to $76.57 the week after.

Afterwards, the Blackmores share price regained momentum and again shot back up near its 52-week high, closing at $87.19 on 15 March.

One month after its FY21 half-year results, Blackmores shares closed at $82.92, a 12% climb, despite no other market-sensitive information during this time.

Considering how its earnings growth was a positive to the Blackmores share price in February, investors will no doubt hope for a similar performance this time around.

This is especially true when factoring the recent run-up on the charts the company's shares have exhibited since May.

At the current Blackmores share price, the company has a market capitalisation of $1.5 billion.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Blackmores Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 ASX shares tipped to climb over 100% in 2026

Analysts expect steep gains this year.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »